Nanobiotix (NBTX) Stock Price, News & Analysis

Company Overview

Nanobiotix is a clinical-stage biotechnology company focused on developing nanomedicine-based therapies for cancer. Headquartered in France, the company uses its proprietary NanoXray technology to design nanoparticles intended to enhance the effects of radiotherapy within solid tumors.

Nanobiotix’s lead product candidate, NBTXR3, is an investigational radioenhancer composed of hafnium oxide nanoparticles. Administered directly into a tumor before radiotherapy, NBTXR3 is designed to increase energy deposition in cancer cells when exposed to X-rays, with the goal of improving tumor control while using established radiation-treatment techniques.

The company is evaluating NBTXR3 in clinical studies across several cancer indications, including locally advanced soft-tissue sarcoma and head and neck cancers, as well as other solid tumors. Nanobiotix was founded in 2003 and is led by co-founder and Chief Executive Officer Laurent Levy. Its activities are directed toward oncology research and development in the United States, Europe and other international markets.

Key Stats

• Today's Range: $23.33 to $24.50
• 50-Day Range: $22.90 to $45.39
• 52-Week Range: $14.78 to $57.14
• Volume: 93,496 shs
• Average Volume: 93,132 shs
• Market Capitalization: $1.20 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.67
• Consensus Rating: Moderate Buy

Nanobiotix Stock Analysis - MarketRank™

Nanobiotix scored higher than 54% of companies evaluated by MarketBeat, and ranked 439th out of 881 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Nanobiotix has a consensus price target of $46.67, representing about 97.1% upside from its current price of $23.68.

Amount of Analyst Coverage

Nanobiotix has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nanobiotix are expected to grow in the coming year, from ($0.62) to $0.16 per share.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.30% of the float of Nanobiotix has been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 1.04, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently decreased by 16.55%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanobiotix does not currently pay a dividend.

Dividend Growth

Nanobiotix does not have a long track record of dividend growth.

News and Social Media

• Score: 0.6 / 5
• News Sentiment: 0.00

News Coverage This Week

MarketBeat has tracked 2 news articles for Nanobiotix this week, compared to 2 articles on an average week.

MarketBeat Follows

1 people have added Nanobiotix to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanobiotix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.45% of the stock of Nanobiotix is held by insiders.

Percentage Held by Institutions

38.81% of the stock of Nanobiotix is held by institutions.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 10/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBTX
• CIK: 1760854
• Web: www.nanobiotix.com
• Phone: 33-1-40-26-04-70
• Fax: N/A
• Employees: 97
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Nanobiotix: $46.67
• High Price Target: $64.00
• Low Price Target: $30.00
• Potential Upside/Downside: +97.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $8.36 million
• Price / Sales: 143.42
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.97) per share
• Price / Book: -12.02

Miscellaneous

• Outstanding Shares: 50,620,000
• Free Float: 48,874,000
• Market Cap: $1.20 billion
• Optionable: Not Optionable
• Beta: 0.79